- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Top Stock Picks from Analysts
Australian Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
26
Companies which are more than 50% undervalued based on analyst price target.
26 companies
Telix Pharmaceuticals
Market Cap: AU$5.2b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$15.38
7D
12.6%
1Y
-25.9%
Clarity Pharmaceuticals
Market Cap: AU$1.4b
A clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States.
CU6
AU$3.74
7D
5.9%
1Y
-57.0%
Opthea
Market Cap: AU$738.8m
A clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States.
OPT
AU$0.60
7D
0%
1Y
23.7%
PYC Therapeutics
Market Cap: AU$586.2m
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$1.01
7D
12.3%
1Y
-44.2%
Clinuvel Pharmaceuticals
Market Cap: AU$561.4m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$11.20
7D
-2.8%
1Y
-21.7%
Race Oncology
Market Cap: AU$540.5m
A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments.
RAC
AU$3.11
7D
21.0%
1Y
71.3%
Immutep
Market Cap: AU$374.3m
A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.26
7D
2.0%
1Y
-26.1%
Botanix Pharmaceuticals
Market Cap: AU$294.2m
Operates as a commercial dermatology company in Australia and the United States.
BOT
AU$0.15
7D
20.0%
1Y
-60.5%
Recce Pharmaceuticals
Market Cap: AU$120.0m
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States.
RCE
AU$0.41
7D
6.4%
1Y
-23.1%
Alterity Therapeutics
Market Cap: AU$119.6m
Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
ATH
AU$0.011
7D
0%
1Y
266.7%
Trajan Group Holdings
Market Cap: AU$112.9m
Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.74
7D
0%
1Y
-40.8%
Paradigm Biopharmaceuticals
Market Cap: AU$111.2m
Engages in the research and development of therapeutic products for human use in Australia.
PAR
AU$0.27
7D
-3.6%
1Y
35.0%
EZZ Life Science Holdings
Market Cap: AU$104.3m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia.
EZZ
AU$2.21
7D
1.4%
1Y
-41.2%
Amplia Therapeutics
Market Cap: AU$82.1m
A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
ATX
AU$0.16
7D
3.2%
1Y
3.2%
Imugene
Market Cap: AU$81.4m
A clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
IMU
AU$0.28
7D
-19.1%
1Y
-83.8%
Vitrafy Life Sciences
Market Cap: AU$79.8m
Engages in the research, development, and commercialization of cryopreservation solutions in Australia.
VFY
AU$1.25
7D
7.8%
1Y
n/a
Medical Developments International
Market Cap: AU$75.5m
Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally.
MVP
AU$0.67
7D
-0.7%
1Y
55.8%
Radiopharm Theranostics
Market Cap: AU$68.6m
A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
RAD
AU$0.029
7D
-14.7%
1Y
-6.5%
Neurizon Therapeutics
Market Cap: AU$64.0m
A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases.
NUZ
AU$0.13
7D
-10.3%
1Y
-35.0%
Genetic Signatures
Market Cap: AU$60.2m
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
GSS
AU$0.27
7D
3.9%
1Y
-60.4%
Proteomics International Laboratories
Market Cap: AU$52.4m
Operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia.
PIQ
AU$0.32
7D
-4.5%
1Y
-54.0%
Cynata Therapeutics
Market Cap: AU$48.7m
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
CYP
AU$0.20
7D
7.9%
1Y
-4.7%
Prescient Therapeutics
Market Cap: AU$44.2m
A clinical stage oncology company, develops drugs for the treatment of various cancers in Australia.
PTX
AU$0.042
7D
0%
1Y
7.7%
Syntara
Market Cap: AU$40.8m
Operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia.
SNT
AU$0.025
7D
-3.8%
1Y
-30.6%
Little Green Pharma
Market Cap: AU$36.7m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.12
7D
-4.0%
1Y
33.3%
Acrux
Market Cap: AU$5.7m
Develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.
ACR
AU$0.014
7D
0%
1Y
-75.0%